Benoit Schmauch

Benoit Schmauch

Auto-generated profile, based on publicly available information

Benoit Schmauch

Owkin, Paris, France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
BSBenoît Schmauch
Benoît Schmauch
ARAlberto Romagnoni
Alberto Romagnoni
EPElodie Pronier
Elodie Pronier
CSCharlie Saillard
Charlie Saillard
PMPascale Maillé
Pascale Maillé
GWGilles Wainrib
Gilles Wainrib
Deep learning methods for digital pathology analysis are an effective way to address multiple clinical questions, from diagnosis to prediction of treatment outcomes. These methods have also been used to predict gene mutations from pathology images, but no comprehensive evaluation of their potential for extracting molecular features from histology slides has yet been performed. We show that HE2RNA, a model based on the integration of multiple data modes, can be trained to systematically predict RNA-Seq profiles from whole-slide images alone, without expert annotation. Through its interpretable design, HE2RNA provides virtual spatialization of gene expression, as validated by CD3- and CD20-staining on an independent dataset. The transcriptomic representation learned by HE2RNA can also be transferred on other datasets, even of small size, to increase prediction performance for specific molecular phenotypes. We illustrate the use of this approach in clinical diagnosis purposes such as the identification of tumors with microsatellite instability.

19 January 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JTJean Ogier du Terrail
Jean Ogier du Terrail
ALArmand Leopold
Armand Leopold
CJClément Joly
Clément Joly
CBConstance Béguier
Constance Béguier
MAMathieu Andreux
Mathieu Andreux
PHPierre Etienne HEUDEL
Pierre Etienne HEUDEL

13 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
CSCharlie Saillard
Charlie Saillard
FDFlore Delecourt
Flore Delecourt
BSBenoit Schmauch
Benoit Schmauch
OMOlivier Moindrot
Olivier Moindrot
MSMagali Svrcek
Magali Svrcek
Jerome CrosJerome Cros
Jerome Cros
Two tumor (Classical/Basal) and stroma (Inactive/active) subtypes of Pancreatic adenocarcinoma (PDAC) with prognostic and theragnostic implications have been described. These molecular subtypes were defined by RNAseq, a costly technique sensitive to sample quality and cellularity, not used in routine practice. To allow rapid PDAC molecular subtyping and study PDAC heterogeneity, we develop PACpAInt, a multi-step deep learning model. PACpAInt is trained on a multicentric cohort (n = 202) and validated on 4 independent cohorts including biopsies (surgical cohorts n = 148; 97; 126 / biopsy cohort n = 25), all with transcriptomic data (n = 598) to predict tumor tissue, tumor cells from stroma, and their transcriptomic molecular subtypes, either at the whole slide or tile level (112 µm squares). PACpAInt correctly predicts tumor subtypes at the whole slide level on surgical and biopsies specimens and independently predicts survival. PACpAInt highlights the presence of a minor aggressive Basal contingent that negatively impacts survival in 39% of RNA-defined classical cases. Tile-level analysis ( > 6 millions) redefines PDAC microheterogeneity showing codependencies in the distribution of tumor and stroma subtypes, and demonstrates that, in addition to the Classical and Basal tumors, there are Hybrid tumors that combine the latter subtypes, and Intermediate tumors that may represent a transition state during PDAC evolution.

27 November 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
BSBenoît Schmauch
Benoît Schmauch
LHLoïc Herpin
Loïc Herpin
AOAntoine Olivier
Antoine Olivier
TDThomas Duboudin
Thomas Duboudin
RDRémy Dubois
Rémy Dubois
EDEric Y. Durand
Eric Y. Durand
Spatial Transcriptomics (spTx) offers unprecedented insights into the spatial arrangement of the tumor microenvironment, tumor initiation/progression and identification of new therapeutic target candidates. However, spTx remains unlikely to be routinely used in the near future. Hematoxylin and eosin (H&E) stained histological slides, on the other hand, are routinely generated for a large fraction of cancer patients. Here, we present a deep learning-based approach for multiscale integration of spTx with tumor morphology (MISO). We train MISO to predict spTx from H&E and validate it on a dataset of 72 10X Genomics Visium samples. We further validate our approach on 348 samples from five indications from the MOSAIC consortium and show that MISO significantly outperforms competing methods in extensive benchmarks. We demonstrate that MISO enables near single-cell-resolution, spatially-resolved gene expression prediction.

24 July 2023 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
YFYu Fu
Yu Fu
MKMarie Karanian
Marie Karanian
RPRaul Perret
Raul Perret
ACAxel Camara
Axel Camara
FLFrançois Le Loarer
François Le Loarer
JCJean-Michel Coindre
Jean-Michel Coindre
Risk assessment of gastrointestinal stromal tumor (GIST) according to the AFIP/Miettinen classification and mutational profiling are major tools for patient management. However, the AFIP/Miettinen classification depends heavily on mitotic counts, which is laborious and sometimes inconsistent between pathologists. It has also been shown to be imperfect in stratifying patients. Molecular testing is costly and time-consuming, therefore, not systematically performed in all countries. New methods to improve risk and molecular predictions are hence crucial to improve the tailoring of adjuvant therapy. We have built deep learning (DL) models on digitized HES-stained whole slide images (WSI) to predict patients’ outcome and mutations. Models were trained with a cohort of 1233 GIST and validated on an independent cohort of 286 GIST. DL models yielded comparable results to the Miettinen classification for relapse-free-survival prediction in localized GIST without adjuvant Imatinib (C-index=0.83 in cross-validation and 0.72 for independent testing). DL splitted Miettinen intermediate risk GIST into high/low-risk groups (p value = 0.002 in the training set and p value = 0.29 in the testing set). DL models achieved an area under the receiver operating characteristic curve (AUC) of 0.81, 0.91, and 0.71 for predicting mutations in KIT, PDGFRA and wild type, respectively, in cross-validation and 0.76, 0.90, and 0.55 in independent testing. Notably, PDGFRA exon18 D842V mutation, which is resistant to Imatinib, was predicted with an AUC of 0.87 and 0.90 in cross-validation and independent testing, respectively. Additionally, novel histological criteria predictive of patients’ outcome and mutations were identified by reviewing the tiles selected by the models. As a proof of concept, our study showed the possibility of implementing DL with digitized WSI and may represent a reproducible way to improve tailoring therapy and precision medicine for patients with GIST.

1 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
IGI. Garberis
I. Garberis
VGV. Gaury
V. Gaury
CSC. Saillard
C. Saillard
DDD. Drubay
D. Drubay
KEK. Elgui
K. Elgui
MLM. Lacroix-Triki
M. Lacroix-Triki
Accurate risk stratification is critical for guiding treatment decisions in early breast cancer. We present an artificial intelligence (AI)-based tool that analyzes digitized tumor slides to predict 5-year metastasis-free survival (MFS) in patients with estrogen receptor-positive, HER2-negative (ER + /HER2 − ) early breast cancer (EBC). Our deep learning model, RlapsRisk BC, independently predicts MFS and provides significant prognostic value beyond traditional clinico-pathological variables (C-index 0.81 vs 0.76, p < 0.05). Applying a 5% MFS event probability threshold stratifies patients into low- and high-risk groups. After dichotomization, combining RlapsRisk BC with clinico-pathological factors increases cumulative sensitivity (0.69 vs 0.63) and dynamic specificity (0.80 vs 0.76) compared to clinical factors alone. Expert analysis of high-impact regions identified by the model highlights well-established morphological features, supporting its interpretability and biological relevance.